Image source: © 2025 Krish Capital Pty.Ltd

Highlights

  • TIVDAK approved in Hong Kong for recurrent or metastatic cervical cancer treatment
  • Company to use ZEJULA infrastructure for immediate product distribution in Hong Kong
  • Biologics License Application under review by China’s NMPA for potential mainland launch

Zai Lab Limited (NASDAQ: ZLAB) announced that Hong Kong’s Department of Health has approved TIVDAK (tisotumab vedotin-tftv), its antibody-drug conjugate (ADC) therapy for adult patients with recurrent or metastatic cervical cancer who experienced disease progression during or after chemotherapy. This marks an important regulatory milestone for the company’s women’s health portfolio in Greater China.

TIVDAK is the first ADC therapy approved for cervical cancer, offering patients a targeted treatment option designed to deliver clinically meaningful survival benefits. The approval enables Zai Lab to bring the drug to patients in Hong Kong without delay. The company confirmed that it will leverage its existing ZEJULA commercial infrastructure to ensure timely distribution and patient access.

“Our goal is to bring innovative therapies to patients in Greater China as quickly as possible,” Zai Lab stated. “With this approval, we can immediately make TIVDAK available to patients in Hong Kong who urgently need new treatment options.”

Beyond Hong Kong, TIVDAK’s Biologics License Application (BLA) is currently under review by China’s National Medical Products Administration (NMPA), following its acceptance in March 2025. If approved, Zai Lab would have access to a significantly larger market across mainland China, where cervical cancer remains a leading cause of cancer-related death among women.

The approval also represents a notable expansion of Zai Lab’s women’s oncology franchise, which already includes ZEJULA for ovarian cancer. Analysts expect that TIVDAK could complement ZEJULA’s market presence and contribute to the company’s revenue diversification in the region.

However, the current approval is limited to patients who have already progressed on chemotherapy, narrowing its eligible patient population. Furthermore, regulatory clearance is presently restricted to Hong Kong, and broader commercial potential depends on a successful outcome of the NMPA review.